Results 291 to 300 of about 1,468,461 (396)

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

MedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun, Dan Huang, Huiling Zhang, Mingyuan Dong, Simiao Wang, Man Sun, Jiayi Liu, Yiqi Wang, Xiaojie Qu, Xuefeng Li, Zhaogang Yang   +10 more
wiley   +1 more source

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum

Pediatric Blood &Cancer, Volume 72, Issue 9, September 2025.
ABSTRACT High‐risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential combinations is even larger.
Steven G. DuBois, Lucas Moreno, John Anderson, Shahab Asgharzadeh, Ro Bagatell, Maja Beck‐Popovic, Jen Belle, Pablo Berlanga, Nick J. Bird, Louis Chesler, Adam Durbin, Angelika Eggert, Martin Eilers, Sara M. Federico, Matthias Fischer, Susanne A. Gatz, Rani E. George, Sally George, Kelly C. Goldsmith, Juliet Gray, Andras Heczey, Meredith S. Irwin, Leona Knox, Holger N. Lode, Donna Ludwinski, Margaret E. Macy, Robbie G. Majzner, John M. Maris, Shakeel Modak, Jan J. Molenaar, Daniel A. Morgenstern, Yael P. Mossé, Cormac Owens, C. Patrick Reynolds, Claudia Rossig, Gudrun Schleiermacher, Liz Scott, Paul M. Sondel, Frank Speleman, Max van Noesel, Frank Westermann, Judith Wienke, Adam J. Wolpaw, Julie R. Park, Andrew D. J. Pearson   +44 more
wiley   +1 more source

GPCR‐G protein signalling and its mutational landscape in cancer—Driver or passenger

British Journal of Pharmacology, Volume 182, Issue 17, Page 3975-3989, September 2025.
G protein‐coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response.
Chenlin Feng, Jasper F. Ooms, Erik H. J. Danen, Laura H. Heitman   +3 more
wiley   +1 more source

Correspondence on 'Characteristics of second primary malignancies following bispecific antibodies therapy' by Liang <i>et al</i>. [PDF]

J Immunother Cancer
Jin Y, Jin Y, Cui Y, Zheng R.
europepmc   +1 more source

Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies

, 2011
Stefanie Koristka, Marc Cartellieri, Anke Theil, Anja Feldmann, Claudia Arndt, Slava Stamova, Irene Michalk, Katrin Töpfer, Achim Temme, Karsten Kretschmer, Martin Bornhäuser, Gerhard Ehninger, Marc Schmitz, Michael Bachmann   +13 more
openalex   +1 more source

Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma

European Journal of Haematology, Volume 115, Issue 3, Page 260-265, September 2025.
ABSTRACT Introduction Bendamustine‐rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B‐cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B‐cell (Hodgkin) lymphoma (NLPBL).
Alexander Robin, Carolyn Owen, Sarah Perry, Lesley Street, Neil Chua, Douglas Stewart, Robert Puckrin   +6 more
wiley   +1 more source

Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection. [PDF]

J Virol
Li M, Chen J, Wang F, Kuang J, Peng Y, Asghar S, Zhao W, Yang Y, Shen C.   +8 more
europepmc   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, Volume 12, Issue 29, August 7, 2025.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies. [PDF]

Biomol Ther (Seoul)
Choi SM, Lee JH, Ko S, Hong SS, Jin HE.
europepmc   +1 more source